2. Caroline Turcotte. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci J. 2016; 73(23)4449–4470. ncbi.nlm.nih.gov/pmc/articles/PMC5075023
3. Luchicchi A1, Pistis M. Anandamide and 2-arachidonoylglycerol: pharmacological
properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol J. 2012 Oct;46(2):374-92. ncbi.nlm.nih.gov/pubmed/22801993
4. Patricia H. Reggio. Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown. Curr Med Chem J. 2010; 17(14): 1468–1486. eurekaselect.com/71427/article
5. Smith SC, Wagner MS. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinology Letter. 2014;35(3):198-201. ncbi.nlm.nih.gov/pubmed/24977967
REFERENCES continued
78 79